Articles by Laura Litwin
Local therapy is recommended by NCCN guidelines, but how it is used in oligoprogressive disease is not well described.
The organization also granted priority review, breakthrough designation, and orphan drug designation to the application.
The study compared results from North America with global results by high-income and low- or middle-income countries.
Palliative care researchers discuss differences in lung cancer treatment disparities across Hispanic patient subgroups.
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
The study compared treatment with neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone.
Efficacy results, safety data, and survival data from the phase 2 study were presented at the ASCO 2025 Annual Meeting.
Study Highlights Relationship Between Lipid Metabolism, NK Cells in the NSCLC Tumor Microenvironment
Study investigators suggested there may be a “promising therapeutic strategy for advancing NK cell-based immunotherapy."
Dr. Weiss noted the results in both feasibility and safety, particularly via injection, which had limited complications.
The study explored the effect of immune checkpoint inhibition on real-world patients with NSCLC versus trial patients.
Nicolas Girard, MD, PhD, discusses data on subcutaneous amivantamab in patients with advanced NSCLC.
Dr. Ladanyi reflects on genetic hotspot mutations that have not been previously well characterized in lung adenocarcinoma.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Final overall survival data from the phase 3 study demonstrated significant benefits for patients with EGFR-mutated aNSCLC.
The study authors evaluated the physical, psychosocial, and lifestyle challenges faced by patients with lung cancer.
Most patients with MPM experience pleural effusion, but questions remain about the condition's impact on patient outcomes.
The NCCN 2025 Annual Conference will be held from March 28-30 in Orlando, Florida.
Expanded treatment options for pleural mesothelioma are "urgently needed," due to the high morbidity of the disease.
Learn how researchers determined the best treatment strategy for smoking cessation among patients who currently smoke.
Clinicians hypothesize that the genetic mutation, known as RUFY1-RET fusion, caused resistance to lorlatinib.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.